MILO/ENGOT-ov11: Phase-3 Study of Binimetinib versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Abstract

Objective: Low-grade serous ovarian carcinomas (LGSOC) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%–60% of LGSOC. A phase II study of the MEK inhibitor selumetinib showed promising response rate of 15% in LGSOC, and binimetinib, a potent MEK1/2 inhibitor, has demonstrated activity across multiple cancers.